Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FHKT9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,523
Award facts
- Contract value 100% obligated
- $19,522.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,522.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The contract, issued on December 29, 2025, with an ultimate completion date of December 30, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy established to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, holding a prime vendor contract (SPE2DR) valued at $499,999,999 with a completion date of December 31, 2036. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, enabling it to fulfill diverse requirements across military healthcare facilities worldwide. As one of multiple regional prime vendor contractors under the PPV-G GEN V program, DMS Pharmaceutical Group leverages its small business status and established performance record to support the Department of Defense's recurring medical supply needs globally.
Quick answers
Who was awarded contract SPE2DR26FHKT9?
SPE2DR26FHKT9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FHKT9 worth?
The government has obligated $19,523 on SPE2DR26FHKT9.
Is contract SPE2DR26FHKT9 an order under another contract?
Yes. SPE2DR26FHKT9 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKT9 competed?
The extent of competition for SPE2DR26FHKT9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award